Trial reportChinese medical journal2026
Efficacy of a single preoperative low-dose dexamethasone on 1-year mortality in geriatric femoral intertrochanteric fracture patients after internal fixation surgery: A randomized, placebo-controlled clinical trial.
Trial report in Chinese medical journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe prognosis of geriatric intertrochanteric fractures (ITF) remains unfavorable even with early surgical treatment due to the fragility associated with aging and stress induced by the fracture. Low-dose dexamethasone has been proposed to improve short-term survival. However, whether a single preoperative dose of low-dose dexamethasone improves survival one year after surgery remains unknown.
methodsThis single-center, single-blinded, randomized, placebo-controlled study was conducted at Guangzhou First People's Hospital. A total of 160 participants admitted between June 2020 and October 2022 were randomly assigned to the dexamethasone group or the placebo group (80 participants per group). The dexamethasone group received 10 mg (2 mL) of dexamethasone and the placebo group received 2 mL of saline intravenously 30 min before surgery. The primary outcome was the prespecified 1-year mortality after surgery. Secondary outcomes included adverse events during hospitalization, Barthel activity of daily living (BADL) score and Parker-Palmer score (PPS) at 30 days, 90 days, 180 days, and 1 year after surgery. Statistical analyses included Studen's t -test or Mann-Whitney U test for quantitative variables, chi-squared test for categorical variables, and Log-rank test for survival differences.
resultsAll participants completed the follow-up. A total of 41 participants died within one year after surgery. There were 15 deaths (18.8%) in the dexamethasone group and 26 deaths (32.5%) in the placebo group (hazard ratio [HR] = 0.51, 95% confidence intervals [CI] = 0.27-0.96, P = 0.04). There were no significant differences in the risk of infection events or hyperglycemia during hospitalization between the dexamethasone and placebo groups ( P >0.05). Although survivors in the dexamethasone group had higher BADL and PPS scores at 30 days, 90 days, 180 days, and 1 year after surgery compared to those in the placebo group, no significant differences were found between the groups at these time points ( P >0.05).
conclusionsA single preoperative low-dose dexamethasone administration reduces 1-year mortality in geriatric ITF patients following internal fixation surgery and may positively impact functional recovery in survivors.
trial registrationChinese Clinical Trial Registry, ChiCTR2200055281.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.